Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 421

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

Open access
Pagano, Gennaro, Taylor, Kirsten I., Anzures-Cabrera, Judith, Marchesi, Maddalena, Simuni, Tanya, Marek, Kenneth, Postuma, Ronald B., Pavese, Nicola, Stocchi, Fabrizio, Azulay, Jean-Philippe, Mollenhauer, Brit, López-Manzanares, Lydia, Russell, David S., Boyd, James T., Nicholas, Anthony P., Luquin, María R., Hauser, Robert A., Gasser, Thomas, Poewe, Werner, Ricci, Benedicte, Boulay, Anne, Vogt, Annamarie, Boess, Frank G., Dukart, Juergen, D’Urso, Giulia, Finch, Rebecca, Zanigni, Stefano, Monnet, Annabelle, Pross, Nathalie, Hahn, Andrea, Svoboda, Hanno, Britschgi, Markus, Lipsmeier, Florian, Volkova-Volkmar, Ekaterina, Lindemann, Michael, Dziadek, Sebastian, Holiga, Štefan, Rukina, Daria, Kustermann, Thomas, Kerchner, Geoffrey A., Fontoura, Paulo, Umbricht, Daniel, Doody, Rachelle, Nikolcheva, Tania, Bonni, Azad·2022·New England Journal of Medicine

Abstract

BACKGROUND: Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease. METHODS: I-ioflupane single-photon-emission computed tomography (SPECT). RESULTS: A total of 316 participants were enrolled; 105 were assigned to receive placebo, 105 to receive 1500 mg of prasinezumab, and 106 to receive 4500 mg of prasinezumab. The baseline mean MDS-UPDRS scores were 32.0 in the placebo group, 31.5 in the 1500-mg group, and 30.8 in the 4500-mg group, and mean (±SE) changes from baseline to 52 weeks were 9.4±1.2 in the placebo group, 7.4±1.2 in the 1500-mg group (difference vs. placebo, -2.0; 80% confidence interval [CI], -4.2 to 0.2; P = 0.24), and 8.8±1.2 in the 4500-mg group (difference vs. placebo, -0.6; 80% CI, -2.8 to 1.6; P = 0.72). There was no substantial difference between the active-treatment groups and the placebo group in dopamine transporter levels on SPECT. The results for most clinical secondary end points were similar in the active-treatment groups and the placebo group. Serious adverse events occurred in 6.7% of the participants in the 1500-mg group and in 7.5% of those in the 4500-mg group; infusion reactions occurred in 19.0% and 34.0%, respectively. CONCLUSIONS: Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. (Funded by F. Hoffmann-La Roche and Prothena Biosciences; PASADENA ClinicalTrials.gov number, NCT03100149.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2202867

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 16 references

Cited by

See all 421

Metadata

Authors
Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Azulay, J.-P., Mollenhauer, B., López-Manzanares, L., Russell, D. S., Boyd, J. T., Nicholas, A. P., Luquin, M. R., Hauser, R. A., Gasser, T., Poewe, W., Ricci, B., Boulay, A., Vogt, A., Boess, F. G., Dukart, J., D’Urso, G., Finch, R., Zanigni, S., Monnet, A., Pross, N., Hahn, A., Svoboda, H., Britschgi, M., Lipsmeier, F., Volkova-Volkmar, E., Lindemann, M., Dziadek, S., Holiga, Š., Rukina, D., Kustermann, T., Kerchner, G. A., Fontoura, P., Umbricht, D., Doody, R., Nikolcheva, T., & Bonni, A.
Venue
New England Journal of Medicine
Published
2022-08-04
Volume
387
Issue
5
Pages
421-432
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4289667141
Cited by
421
References
16
FWCI
37.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial of Prasinezumab in Early-Stage Parkinson’s Disease. https://app.cochat.ai/papers/10.1056/nejmoa2202867
The paper
Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Azulay, J.-P., Mollenhauer, B., López-Manzanares, L., Russell, D. S., Boyd, J. T., Nicholas, A. P., Luquin, M. R., Hauser, R. A., Gasser, T., Poewe, W., . . . Bonni, A. (2022). Trial of Prasinezumab in Early-Stage Parkinson’s Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2202867

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.